Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals.
Janie Parrino, Lewis H McCurdy, Brenda D Larkin, Ingelise J Gordon, Steven E Rucker, Mary E Enama, Richard A Koup, Mario Roederer, Robert T Bailer, Zoe Moodie, Lin Gu, Lihan Yan, Barney S Graham
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naive and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
All material on this website is protected by copyright, Copyright ⓒ 1994-
2024
by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our
terms of use
and
privacy policy
.
Your Privacy Choices